RxDoctor Payments Data

Ericka Flood, MD

Family Medicine · Gonzales, LANPI 1346419462

Payments from drug & device makers

$10,726in general payments, 2019–2025

Across 701 payments — averaging $15.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AbbVie$1K
  • Bausch Health US, LLC$804
  • Takeda Pharmaceuticals U.S.A., Inc.$489
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$488
  • Amarin Pharma, Inc.$479
  • plus $5K from 51 others

What the payments were for

  • Speaking & faculty fees$8007%
  • Food & beverage$9,89492%
  • Education$320%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk179$2,097
AbbVie(2 entities)82$1,096
Bausch Health US, LLC57$804
Takeda Pharmaceuticals U.S.A., Inc.29$489
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC37$488
Amarin Pharma, Inc.29$479
Aytu Biopharma, Inc.5$452
Tandem Diabetes Care, Inc.1$400
Amgen(2 entities)23$376
Lilly USA, LLC24$289
IBSA Pharma Inc.16$289
Abbott15$272
Sanofi-aventis U.S. LLC20$267
Bayer15$252
AstraZeneca15$227
Astellas Pharma US Inc11$189
Merck13$188
Eisai Inc.10$188
Antares Pharma, Inc.9$148
Novartis9$144
Teva Pharmaceuticals USA, Inc.9$138
Supernus Pharmaceuticals, Inc.8$129
Kowa Pharmaceuticals America, Inc.7$107
Boehringer Ingelheim6$97
Esperion Therapeutics, Inc.5$94
Currax Pharmaceuticals LLC6$79
Zealand Pharma US, Inc.4$75
Endo Pharmaceuticals Inc.4$70
Clarus Therapeutics Inc.5$68
GSK3$60
Dexcom, Inc.3$60
Kvk-tech, Inc.6$59
Sunovion Pharmaceuticals Inc.2$45
Vivus LLC3$38
Rochester Medical Corporation1$35
Therapeuticsmd, Inc.2$35
Alfasigma USA, Inc.2$33
Acerus Pharmaceuticals Corporation2$32
Johnson & Johnson2$31
Jazz Pharmaceuticals Inc.2$30
Amneal Pharmaceuticals LLC2$26
Shire North American Group Inc2$26
Daiichi Sankyo Inc.1$24
Xeris Pharmaceuticals, Inc.2$24
Renalytix AI, Inc.1$18
Lundbeck LLC1$16
Insulet Corporation1$15
Pfizer1$14
Duchesnay USA Incorporated1$14
Neos Therapeutics, LP1$14
Biohaven Pharmaceutical Holding Company Ltd.1$13
Millicent US Inc1$12
Impel Pharmaceuticals Inc.1$12
Medtronic1$12
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)1$12
Adlon Therapeutics L.p.1$12
Biohaven Pharmaceuticals, Inc.1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,726 in reported general payments places this provider in the 90th percentile of 1,469 family medicine providers in Louisiana.

See all family medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$6,054
Medicare patients
43
Services billed
49

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide175$194,910
OzempicSemaglutide93$142,872
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/734$40,574
JardianceEmpagliflozin32$32,481
FarxigaDapagliflozin Propanediol17$21,611
VascepaIcosapent Ethyl28$18,931
Trijardy XrEmpaglifloz/Linaglip/Metformin15$14,444
JanuviaSitagliptin Phosphate11$14,122
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog21$14,035
RybelsusSemaglutide14$13,046
Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt17$12,978
Humalog Kwikpen U-200Insulin Lispro13$10,002
Icosapent Ethyl12$5,830
NovologInsulin Aspart22$5,827
SynthroidLevothyroxine Sodium90$5,660

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Humalog$289$198,329190 claims
Novo NordiskOzempic, Rybelsus, Novolog$2,097$161,744129 claims
Boehringer IngelheimJardiance, Trijardy Xr$97$46,92547 claims
AstraZenecaFarxiga$227$21,61117 claims
MerckJanuvia$188$14,12211 claims
AbbVieSynthroid, Armour Thyroid$1,096$6,863103 claims
Amneal Pharmaceuticals LLCUnithroid, Levothyroxine Sodium$26$4,146225 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,469 family medicine providers in Louisiana.

Other family medicine in Gonzales

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →